Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $172.00.
Sarepta Therapeutics (SRPT) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Sarepta Therapeutics (
SRPT
–
Research Report
), with a price target of
$172.00
. The company’s shares c
BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley
03:27pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on BeiGene (BGNE), with a price target of $184.00. The company's
Galapagos (GLPG) Receives a Hold from Morgan Stanley
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Galapagos (GLPG) today and set a price target of $226.00. The company's shares closed
Morgan Stanley Believes Vertex Pharmaceuticals (VRTX) Won't Stop Here
03:26pm, Wednesday, 15'th Apr 2020
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Vertex Pharmaceuticals (VRTX), with a price target of $258.00.
Morgan Stanley Believes Vertex Pharmaceuticals (NASDAQ: VRTX) Won’t Stop Here
03:26pm, Wednesday, 15'th Apr 2020
In a report released today,
Matthew Harrison
from Morgan Stanley maintained a
Buy
rating on Vertex Pharmaceuticals (
VRTX
–
Research Report
), with a price target of
$258.00
. The company’s shares
Morgan Stanley Remains a Hold on Regeneron (REGN)
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron (REGN) today and set a price target of $409.00. The company's shares closed
Morgan Stanley Remains a Hold on Regeneron (REGN)
03:26pm, Wednesday, 15'th Apr 2020
Morgan Stanley analyst
Matthew Harrison
maintained a
Hold
rating on Regeneron (
REGN
–
Research Report
) today and set a price target of
$409.00
. The company’s shares closed last Wednesday at $51
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Amgen (AMGN) and Eli Lilly & Co (LLY)
03:25pm, Wednesday, 15'th Apr 2020
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN), Amgen (AMGN) and Eli Lilly & Co
Alnylam Pharma (ALNY) Receives a Sell from Nomura
01:07pm, Tuesday, 14'th Apr 2020
Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharma (ALNY) today and set a price target of $74.00. The company's shares closed
Alnylam Pharma (ALNY) Receives a Sell from Nomura
01:07pm, Tuesday, 14'th Apr 2020
Nomura analyst Christopher Marai maintained a Sell rating on Alnylam Pharma (ALNY – Research Report) today and set a price
Nuveen Asset Management LLC Has $20.53 Million Stock Holdings in Global Blood Therapeutics Inc (NASDAQ:GBT)
09:38am, Monday, 13'th Apr 2020
Nuveen Asset Management LLC lowered its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 47.9% in the 4th quarter, according to its most recent disclosure with the SEC. The fund own
9mobile Supports Mobihealth International to Combat COVID-19 | BizWatchNigeria.Ng
11:00pm, Sunday, 12'th Apr 2020
Nigeria’s leading telecoms service provider, 9mobile, has thrown its weight behind Mobihealth international, an award-winning telemedicine provider, to...
Global Blood Therapeutics (NASDAQ:GBT) Stock Rating Upgraded by BidaskClub
11:30am, Sunday, 12'th Apr 2020
BidaskClub upgraded shares of Global Blood Therapeutics (NASDAQ:GBT) from a sell rating to a hold rating in a report published on Thursday, BidAskClub reports. GBT has been the topic of several other
Incyte (INCY) Receives a Buy from Nomura
11:23am, Wednesday, 08'th Apr 2020
In a report issued on April 6, Christopher Marai from Nomura maintained a Buy rating on Incyte (INCY), with a price target of $116.00. The company's
